NCT06942507View on ClinicalTrials.gov

Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

NANot yet recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2029

Conditions
Waldenström's Macroglobulinemia (WM)
Interventions
DRUG

Zanubrutinib

zanubrutinib 160mg po bid d1-28

DRUG

Bendamustine + Rituximab

bendamustine 70-90mg/m2 ivgtt d1-2, rituximab 375mg/m2 ivgtt d1

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER